CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 304 enrolled
Drug / intervention
IMVAMUNE +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00686582
NCT00686582Phase 2Completed
CompareCT.gov

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Bavarian Nordic·interventional·Posted May 30, 2008·Updated Mar 13, 2019

In Brief

A Phase 2 clinical trial evaluating IMVAMUNE and Blood Draw Only for Smallpox. Completed, enrolled 304 participants across 1 site.

Detailed Summary

The study was preformed to evaluate the persistence of antibodies following vaccination with MVA-BN and to assess the immunological memory response induced by a booster vaccination with MVA-BN in subjects two years after their participation in trial POX-MVA-005 (NCT00316524) in which they had received one or two doses of MVA-BN.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmallpox
CountriesGermany
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 30, 2008
Enrollment StartAug 1, 2008
Primary CompletionDec 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.1 years ago

Interventions

IMVAMUNEbiological

1x 10E8\_TCID50

IMVAMUNEbiological

1x 10E8\_TCID50

Blood Draw Onlyprocedure